Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Retrovirus Life Cycles01:10

Retrovirus Life Cycles

50.2K
Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the...
50.2K
Retroviruses02:33

Retroviruses

15.6K
Retroviruses and retrotransposons both insert copies of their genetic elements into the genome of the host cell. Thus, the viral genes are passed on when the host genome is replicated or translated. A typical retroviral DNA sequence contains 3-4 genes that encode the different proteins required for its structural assembly and function as a molecular parasite. This DNA is transcribed into a single mRNA, which is very similar in structure to conventional mRNAs, i.e., it is capped at the 5’...
15.6K
Size and Structure of Viral Genomes01:26

Size and Structure of Viral Genomes

987
Viral genomes exhibit remarkable diversity in size, structure, and composition, influencing their replication strategies and interactions with host cells. These genomes consist of either DNA or RNA and may be linear or circular. Additionally, they can be single-stranded or double-stranded, with each configuration affecting how the virus propagates within a host. RNA viruses, for instance, generally have smaller genomes than DNA viruses, a factor that contributes to their high mutation rates and...
987
Viruses with RNA Genomes01:29

Viruses with RNA Genomes

1.2K
RNA viruses are categorized into positive-strand, negative-strand, or double-stranded groups based on their genomic structure and replication mechanisms. This classification dictates how they exploit host cellular machinery for protein synthesis and replication. Some RNA viruses also utilize reverse transcription as part of their life cycle, further diversifying their replication strategies.Positive-Strand RNA VirusesPositive-strand RNA viruses have genomes that function directly as messenger...
1.2K
Non-LTR Retrotransposons03:18

Non-LTR Retrotransposons

13.8K
As the name suggests, non-LTR retrotransposons lack the long terminal repeats characteristic of the LTR retrotransposons. Additionally, both LTR and non-LTR retrotransposons use distinct mechanisms of mobilization. Non-LTR retrotransposons are further divided into two classes - Long interspersed nuclear elements (LINEs) and short interspersed nuclear elements (SINEs), both of which occur abundantly in most mammals, including humans. Some of the active non-LTR retrotransposons in humans are L1...
13.8K
LTR Retrotransposons03:08

LTR Retrotransposons

20.2K
LTR retrotransposons are class I transposable elements with long terminal repeats flanking an internal coding region. These elements are less abundant in mammals compared to other class I transposable elements. About 8 percent of human genomic DNA comprises LTR retrotransposons. Some of the common examples of LTR retrotransposons are Ty elements in yeast and Copia elements in Drosophila.
The internal coding region of LTR retrotransposons and their mechanism of transposition closely resembles a...
20.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cell-based platforms for antiviral screening against hepatitis B virus: advantages, limitations, and future perspectives.

Antiviral research·2026
Same author

Retraction notice to "Evaluating the efficacy and safety of a novel prophylactic nasal spray in the prevention of SARS-CoV-2 infection: A multi-centre, double blind, placebo-controlled, randomised trial" [J. Clin. Virol. 155C (2022) 105248].

Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology·2025
Same author

Long-term 3D cell culture models for hepatitis B virus studies.

Virology·2024
Same author

Investigating the role of phenylalanine residues for amyloid formation of the neuropeptide neurokinin B.

Biochemical and biophysical research communications·2024
Same author

Preservation of memory B cell homeostasis in an individual producing broadly neutralising antibodies against HIV-1.

bioRxiv : the preprint server for biology·2024
Same author

Effect of a 2-week interruption in methotrexate treatment on COVID-19 vaccine response in people with immune-mediated inflammatory diseases (VROOM study): a randomised, open label, superiority trial.

The Lancet. Rheumatology·2024

Related Experiment Video

Updated: Mar 13, 2026

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
05:46

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors

Published on: April 9, 2014

18.5K

Retroviral restriction: nature's own solution.

Christopher E Jones1, Áine McKnight

  • 1The Centre for Immunobiology, Blizard Institute, Queen Mary University of London, London, UK.

Current Opinion in Infectious Diseases
|October 27, 2016
PubMed
Summary
This summary is machine-generated.

New anti-HIV therapies leverage host restriction factors to combat the virus. By targeting viral evasion or boosting natural defenses, these promising treatments offer novel strategies against HIV infection.

More Related Videos

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
10:29

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

2.6K
High Throughput In Vitro Assessment of Latency Reversing Agents on HIV Transcription and Splicing
07:18

High Throughput In Vitro Assessment of Latency Reversing Agents on HIV Transcription and Splicing

Published on: January 22, 2019

6.3K

Related Experiment Videos

Last Updated: Mar 13, 2026

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
05:46

Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors

Published on: April 9, 2014

18.5K
Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors
10:29

Quantitative Structure-Activity Relationship, Activity Prediction, and Molecular Dynamics of Non-nucleotide Reverse Transcriptase Inhibitors

Published on: May 9, 2025

2.6K
High Throughput In Vitro Assessment of Latency Reversing Agents on HIV Transcription and Splicing
07:18

High Throughput In Vitro Assessment of Latency Reversing Agents on HIV Transcription and Splicing

Published on: January 22, 2019

6.3K

Area of Science:

  • Immunology
  • Virology
  • Therapeutics

Background:

  • Host restriction factors naturally inhibit HIV replication.
  • HIV has evolved accessory factors to counteract these host defenses.
  • Understanding this interplay is crucial for developing new treatments.

Purpose of the Study:

  • To review recent advances in anti-HIV therapies.
  • To explore strategies inspired by host restriction factor mechanisms.
  • To discuss therapeutic manipulation of host-virus interactions.

Main Methods:

  • Review of current scientific literature on HIV restriction factors.
  • Analysis of therapeutic strategies targeting host-pathogen interactions.
  • Discussion of preclinical and clinical trial data.

Main Results:

  • Therapeutic approaches aim to inhibit viral evasion of restriction factors.
  • Strategies also focus on increasing intracellular levels of restriction factors.
  • Several promising therapies are advancing into clinical trials.

Conclusions:

  • Host restriction factors represent viable targets for anti-HIV drug development.
  • Further research into manipulating these factors is warranted.
  • Targeting host immunity offers a promising avenue for HIV treatment.